TVTX - Company ID 0001438533
The table below shows Travere Therapeutics, Inc.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q1 2025 | Q1 2024 | Q1 2023 | Q1 2022 | Q1 2021 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$40.37M | -$42.19M | -$119.00M | -$81.12M | -$55.32M | -$26.47M |
| Capital expenditure | - | - | $0.00 | $630.00K | $131.00K | $4.50M |
| Investing cash flow | $21.55M | $41.29M | $104.90M | -$37.04M | $33.16M | -$105.71M |
| Dividends paid | - | - | - | - |
Travere Therapeutics, Inc. reported operating cash flow of $37.78M for fiscal year 2025. That is up 115.9% from -$237.47M in fiscal 2024. Over the 10 fiscal years shown, operating cash flow grew from -$3.44M (FY 2016) to $37.78M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $4.20M | $3.72M | -$525.00K | $217.00M | $113.91M | $195.75M |